Fig. 5: Riclin mitigates GEM-induced immunosuppression.
From: Natural polysaccharide riclin acts as an immune adjuvant to enhance chemotherapy efficacy in NSCLC
Experimental timeline and dosing regimen (A). Body weight (B). Organ indices: Thymus (C) and Spleen (D). Peripheral blood counts: WBCs (E), RBCs (F), LYMPH (G), NE (H), and platelets (I). Histology of spleen (Scale bar: 100 μm, 50 μm) (J) and bone marrow (Scale bar: 20 μm) (K). Flow cytometric quantification of splenic total cells (L), CD3⁺ T cells (M), CD3⁺CD4⁺ T cells (N), CD3⁺CD8⁺ T cells (O), and CD11b⁺F4/80⁺ macrophages (P). Spleen (Q) and serum levels (R) of TNF-α, IL-1β, and IL-6. Data represent mean ± SD (n = 4–11); *p < 0.05, **p < 0.01, ***p < 0.001 vs. CK; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. GEM group.
